Medtronic is making available in the United States its Endeavor® Sprint Zotarolimus-Eluting Stent, a popular device in Europe and elsewhere, that features company’s next-generation stent delivery platform:
Using the popular Sprinter™ balloon catheter technology, the Endeavor Sprint system puts the highly deliverable Endeavor DES on an enhanced delivery platform, making Medtronic’s flagship DES even easier for physicians to deliver to the site of coronary blockages. The Endeavor Sprint system incorporates a new tip design for a low profile, a new balloon material and an enhanced shaft design which together greatly improve the device’s deliverability.
The robust ENDEAVOR clinical program has demonstrated that the Endeavor stent is associated with exceptionally low rates of stent thrombosis, myocardial infarction and cardiac death, as well as low and comparable rates of clinically-driven target lesion revascularization, out to as long as five years of patient follow-up. Representing various world geographies and patient subsets, the program has enrolled more than 10,000 subjects to date and will ultimately enroll more than 20,000 subjects in a combination of randomized controlled and single-arm clinical trials.
Press release: Medtronic Launches Endeavor® Sprint Drug-Eluting Stent System on Rapid Exchange in United States …
Product page: Endeavor® Sprint…